Literature DB >> 20398039

Induction concurrent chemoradiotherapy compared with induction radiotherapy for superior sulcus non-small cell lung cancer: a retrospective study.

Jian Li1, Chun-Hua Dai, Shun-Bing Shi, Qian-Lei Bao, Li-Chao Yu, Jian-Rong Wu.   

Abstract

AIM: To evaluate the efficacy of current chemoradiotherapy on improvement of survival in patients with superior sulcus non-small cell lung cancer (NSCLC).
METHODS: We retrospectively reviewed the data of 39 patients with superior sulcus NSCLC treated with induction therapy followed surgery. The patients were divided into two groups according to the induction approach: the induction radiotherapy (RT) group (1993-1999), and the induction chemoradiotherapy (CT/RT) group (since 1999).
RESULTS: The rate of complete resection was 65 percent in the RT group (n = 17) compared with 91 percent in the CT/RT group (n = 22, P = 0.024). Complete pathological responses from induction therapy were 12 percent in the RT group and 45 percent in the CT/RT group (P = 0.032). Overall survival (OS) was significantly longer in patients who received CT/RT than that in those who received RT, with 2- and 5-year survival rates of 77.3 percent and 36.4 percent versus 41.2 percent and 11.8 percent, respectively (P = 0.007). CT/RT also associated with a markedly longer tumor-free survival (TFS), with a median TFS of 40 and 17 months, respectively (P = 0.007). Patients achieved complete resection or complete pathological response had a significantly better survival than those with incomplete resection or pathological partial responses and no change (P < 0.0005 and P = 0.001, respectively).
CONCLUSION: Our results indicate that CT/RT followed by surgery can significantly improve OS and TFS, and may be considered as an optimal option in treatment of patients with superior sulcus NSCLC.

Entities:  

Mesh:

Year:  2010        PMID: 20398039     DOI: 10.1111/j.1743-7563.2009.01265.x

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  3 in total

1.  Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.

Authors:  Nan Jiang; Xiao-Cen Chen; Yue Zhao
Journal:  Support Care Cancer       Date:  2012-08-31       Impact factor: 3.603

2.  Evaluation of arm function and quality of life after trimodality treatment for superior sulcus tumours.

Authors:  Ramon R Gorter; Cornelis G Vos; Janine Halmans; Koen J Hartemink; Marinus A Paul; Jan Wolter A Oosterhuis
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-10-09

Review 3.  Superior sulcus tumors (Pancoast tumors).

Authors:  Giuseppe Marulli; Lucia Battistella; Marco Mammana; Francesca Calabrese; Federico Rea
Journal:  Ann Transl Med       Date:  2016-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.